The aim of the respiratory biomedical research unit (BRU) is to increase the number of new products (therapeutic agents, devices or biomarkers) entering phase I and II clinical trials for advanced lung disease.

This will be achieved by focusing on the following four key areas:

• Disease-based consortia
  Consortia and cross-cutting themes have been established representing different specialist areas of advanced lung diseases. Each consortium brings together scientists, clinicians, industrial partners and patients. If you are an academic or industry representative who would like to understand more about what the BRU can offer, please contact the project manager Tracy Higgins.

• Core facilities
  A wide range of clinical and scientific core facilities are available for translational respiratory disease research. If you are an academic or industry representative who would like to understand more about what facilities the BRU can offer, please contact the project manager Tracy Higgins.

• Translational medicine education programme
  Training, seminars and courses in advanced lung diseases are available for clinicians, scientists and allied healthcare professionals. If you would like to understand more about the studentships on offer, please contact the education director Dr Mark Griffiths.

• Patients and public involvement
  A patient and public involvement (PPI) programme to promote and encourage patients and the public to participate in our research projects. If you are a patient or member of the public wishing to become involved in clinical trials we are currently running, please contact the PPI lead Zahra Aden.

Key personnel